Evidence map›Paper›PMID 31734530›Full record

ArticleNeuroImage. Clinical2019

Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process.

Liane S Canas, Carole H Sudre, Enrico De Vita, Akin Nihat, Tze How Mok, Catherine F Slattery, Ross W Paterson, Alexander J M Foulkes, Harpreet Hyare, M Jorge Cardoso and 7 more

Open access · goldAbstract read
In one paragraph

Article in NeuroImage. Clinical, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Insights into the Diagnosis, Treatment, and Management of Prion Diseases.CNS & neurological disorders drug targets · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Liane S CanasDepartment of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom; School of Biomedical Engineering & Imaging Sciences, King's College London, King's Health Partners, St Thomas' Hospital, London, SE1 7EH, United Kingdom. Electronic address: rmaplsc@ucl.ac.uk.
Carole H SudreDepartment of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom; School of Biomedical Engineering & Imaging Sciences, King's College London, King's Health Partners, St Thomas' Hospital, London, SE1 7EH, United Kingdom; Dementia Research Centre, UCL Institute of Neurology, 8-11 Queen Square, London, WC1N 3BG, UK.
Enrico De VitaInstitute of Neurology, University College London, United Kingdom; School of Biomedical Engineering & Imaging Sciences, King's College London, King's Health Partners, St Thomas' Hospital, London, SE1 7EH, United Kingdom.
Akin NihatMRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, United Kingdom; NHS National Prion Clinic, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Tze How MokMRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, United Kingdom; NHS National Prion Clinic, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Catherine F SlatteryDementia Research Centre, UCL Institute of Neurology, 8-11 Queen Square, London, WC1N 3BG, UK.
Ross W PatersonDementia Research Centre, UCL Institute of Neurology, 8-11 Queen Square, London, WC1N 3BG, UK.
Alexander J M FoulkesDementia Research Centre, UCL Institute of Neurology, 8-11 Queen Square, London, WC1N 3BG, UK.
Harpreet HyareNHS National Prion Clinic, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
M Jorge CardosoDepartment of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom; School of Biomedical Engineering & Imaging Sciences, King's College London, King's Health Partners, St Thomas' Hospital, London, SE1 7EH, United Kingdom.
John ThorntonInstitute of Neurology, University College London, United Kingdom.
Jonathan M SchottDementia Research Centre, UCL Institute of Neurology, 8-11 Queen Square, London, WC1N 3BG, UK.
Frederik BarkhofDepartment of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom; Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
John CollingeMRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, United Kingdom; NHS National Prion Clinic, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Sébastien OurselinDepartment of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom; School of Biomedical Engineering & Imaging Sciences, King's College London, King's Health Partners, St Thomas' Hospital, London, SE1 7EH, United Kingdom.
Simon MeadMRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, United Kingdom; NHS National Prion Clinic, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Marc ModatDepartment of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom; School of Biomedical Engineering & Imaging Sciences, King's College London, King's Health Partners, St Thomas' Hospital, London, SE1 7EH, United Kingdom.
St Thomas' Hospital · GBUniversity College London Hospitals NHS Foundation Trust · GBUK Dementia Research Institute · GBAmsterdam University Medical Centers · NLUniversity College London · GB

Funding

EPA EP-W-17-011Medical Research Council G0400713Medical Research Council MC_U123160651Medical Research Council MC_U123160657Medical Research Council MC_UU_00024/1Medical Research Council MC_UU_00024/9Wellcome Trust
6 · The paper itself

Abstract

Prion diseases are a group of rare neurodegenerative conditions characterised by a high rate of progression and highly heterogeneous phenotypes. Whilst the most common form of prion disease occurs sporadically (sporadic Creutzfeldt-Jakob disease, sCJD), other forms are caused by prion protein gene mutations, or exposure to prions in the diet or by medical procedures, such us surgeries. To date, there are no accurate quantitative imaging biomarkers that can be used to predict the future clinical diagnosis of a healthy subject, or to quantify the progression of symptoms over time. Besides, CJD is commonly mistaken for other forms of dementia. Due to the heterogeneity of phenotypes and the lack of a consistent geometrical pattern of disease progression, the approaches used to study other types of neurodegenerative diseases are not satisfactory to capture the progression of human form of prion disease. In this paper, using a tailored framework, we aim to classify and stratify patients with prion disease, according to the severity of their illness. The framework is initialised with the extraction of subject-specific imaging biomarkers. The extracted biomakers are then combined with genetic and demographic information within a Gaussian Process classifier, used to calculate the probability of a subject to be diagnosed with prion disease in the next year. We evaluate the effectiveness of the proposed method in a cohort of patients with inherited and sporadic forms of prion disease. The model has shown to be effective in the prediction of both inherited CJD (92% of accuracy) and sporadic CJD (95% of accuracy). However the model has shown to be less effective when used to stratify the different stages of the disease, in which the average accuracy is 85%, whilst the recall is 59%. Finally, our framework was extended as a differential diagnosis tool to identify both forms of CJD among another neurodegenerative disease. In summary we have developed a novel method for prion disease diagnosis and prediction of clinical onset using multiple sources of features, which may have use in other disorders with heterogeneous imaging features.

Indexed as

AdultAgedAtrophyBiomarkersBrainDiagnosis, DifferentialDisease ProgressionFemaleHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedNeurodegenerative DiseasesNeuroimagingPhenotypeBiomarkersBiomarkersDiagnosisGaussian processInherited Creutzfeldt–Jakob diseasePrion diseasesSporadic Creutzfeldt–Jakob diseaseSubjects’ stratification

Identifiers

PMID31734530
PMCPMC6978211
OpenAlexW2981499243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.